gut.bmj2mon
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
Design Patients were randomised 1:1:1:1 to receive budesonide MMX 9 mg or 6 mg, or Entocort EC 9 mg (budesonide controlled ileal-release capsules; reference arm) or placebo once daily for 8 weeks. The ...
gut.bmj2mon
Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial
The primary objective of the study was to demonstrate the superiority of pH-modified release oral budesonide (Budenofalk 3 mg capsules, Dr Falk Pharma GmbH, Freiburg, Germany) compared with placebo ...